AstraZeneca Plc. announced on Thursday that its revenue in the fourth quarter of its fiscal 2024 rose by 24% on an annual basis to $14.9 billion, exceeding analysts' expectations. For the full 2024, total revenue jumped by 21% to $54.1 billion.
The company's diluted earnings per share (EPS) increased to $0.96 in the reported quarter and to $4.50 for the full 2024. Operating profit grew by % year-on-year to $2.1 billion, while product sales climbed by 18% to $13.4 billion. The pharmaceutical company announced that its dividend will be further increased for the full year 2025.
"Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19%, respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025," CEO Pascal Soriot stated.